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Background: Atrial fibrillation (AF) patients with a previous stroke are often at a high risk of recurrent stroke and bleeding. Anticoagulation therapy in such a populationpatients is a challenging dilemma. Currently, thoracoscopic left atrial appendage excision (LAAE) plus AF ablation is an  standardinterventional approach offered to for some AF patients. We hypothesized that this approach is the most suitablemay be suitable as a secondary stroke prevention strategy for these “double-high-risk” patients.
Methods: Between January 2013 and December 2016, a total of 44 patients (26 male; mean age 65.0±9.1 yearss) with nonvalvular AF and a previous stroke or systemic thromboembolic event were enrolled in our study. The patients underwent thoracoscopic LAAE plus AF ablation by experienced operators and were followed up for 2 years (at 1, 3, 6, 9, and 12 months postoperatively and every 6 months thereafter). T for thromboembolic and major bleeding events were recorded. Cerebral computed tomography or magnetic resonance imaging and 7-day Holter monitoring were performed annually.
Results: The mean age of the study group was 65.0±9.1 years. The mMean CHA2DS2-VASc and HAS-BLED scores were 4.2±1.2 and 3.3±0.7, respectively. All patients discontinued oral anticoagulation (OAC) therapy after the surgical intervention. One patient suffered a periprocedural transient ischemic attack, and another was diagnosed with a new ischemic stroke at 491 days after surgery. 
The annual rate of total thromboembolism was 2.05%. No deaths or major bleeding events were observed postoperatively. The overall AF control rate was 65.9%.
Conclusion: Trans-thoracoscopic LAAE plus AF ablation may beis a promising approach for this “double-high-risk” population due to its AF control and appendectomy. Prophylaxis for Tthromboembolism prevention in such patientsthis secondary prevention cohort was low, even can be achieved without anticoagulation OAC treatment.







cLAA=Complete excision of LAA 
iLAA=Incomplete excision of LAA
LAA=Left atrial appendage
LAAE=Left atrial appendage excision
LAAO=Left atrial appendage occlusion






Oral anticoagulation (OAC) therapy for the prevention of thromboembolism in atrial fibrillation (AF) patients is similar tohas been described as “a double-edged sword.” Although OAC with warfarin it dramatically reduces the rate of ischemic stroke and systemic thromboembolism, it also increases the risk of bleeding, particularly if warfarin management is poor 1 [refs].2. In Asian countries, AF patients with the same CHA2DS22-VASc scores normally have an increased risk of thromboembolism compared with non-Asian populations, but when OAC therapy is used, the rate of bleeding events is even higher 3-5. 

The greatest dilemma of OAC therapy is typically in AF patients with a previous thromboembolism. This is a special population with a high risk of recurrent thromboembolism and a high risk of bleeding (double-high-risk). To avoid bleeding, especially intracranial bleeding, in such patients, OAC therapy for secondary prevention is sometimes under-rarely prescribed 6.7; however, this approach greatly increases the risk of recurrent thromboembolism in such patients 8.

Thoracoscopic surgical AF ablation is a technique that was developed over the past decade 9.10.11. It This consists of pulmonary vein epicardial bipolar ablation and left atrial appendage excision (LAAE). Currently, thoracoscopic left atrial appendage excision (LAAE) plus AF ablation is an interventional approach offered to some AF patients. We hypothesized that this approach may be suitable as a secondary stroke prevention strategy for these high-risk patients.




Between January 2013 and December 2016, a total of 44 patients with nonvalvular AF and a previous stroke or systemic thromboembolic event who underwent thoracoscopic LAAE plus AF ablation by experienced operators at the First Affiliated Hospital of Nanjing Medical University were enrolled in this study.





This was a prospective observational cohort study. The study protocol was approved by the Institutional Review Board of the First Affiliated Hospital of Nanjing Medical University.

Outcomes
The primary outcome was thromboembolic events, including TIA, ischemic stroke, and noncentral nervous systemic embolism. The secondary outcomes were major bleeding as defined by the International Society on Thrombosis and Hemostasis criteria, AF recurrence and all-cause death.

Thoracoscopic LAAE plus AF ablation
All patients underwent general anesthesia with a double-lumen endotracheal tube for selective single-lung ventilation. Transesophageal echocardiography (TEE) was performed before ablation to verify the absence of a left atrial thrombus and guide LAA resection. The patients were placed in the supine position with bilateral forearms alongside the body and slightly below the table to expose the axillary regions. The procedure was performed through three ports in the chest wall. First, the procedure was begun on the right side after left single-lung ventilation. The camera port (5 mm) was placed in the fourth intercostal space on the midaxillary line, and the remaining two working ports (5 mm and 12 mm) were placed in the third and fifth intercostal spaces on the anterior-axillary line, respectively. Carbon dioxide insufflation was used to expand the operative field at 8-10 mm Hg. The right-side pericardium was opened at 2 cm anterior to the phrenic nerve. Retraction sutures were used to facilitate the exposure. After blunt dissection of the oblique and transverse sinus, an AtriCure Lumitip Dissector (AtriCure, Inc., Cincinnati, Ohio) was introduced around the pulmonary veins. Pulmonary vein isolation was achieved with an AtriCure Isolator Synergy ablation clamp (AtriCure, Inc., Cincinnati, Ohio) around the pulmonary vein antrum at least six times. Ganglionated plexus identification and ablation were performed using an AtriCure Synergy ablation pen (AtriCure, Inc., Cincinnati, Ohio). The additional superior and inferior ablation lines connecting the bilateral pulmonary vein isolations were created by applying the AtriCure Synergy ablation pen. Following completion of the ablation on the right side, ablation on the left side was accomplished in a similar manner. Three ports were placed in the same intercostal spaces but more posterior than on the right side. The left-side pericardium was opened posterior to the phrenic nerve. The ligament of Marshall was dissected by electrical cautery. Conduction block was confirmed upon completion of the ablation procedure on the left side. The LAA excision site was closed with an endoscopic EZ 60 stapler (Ethicon EndoSurgery, Inc., Cincinnati, Ohio) under TEE guidance. Finally, cardioversion was performed immediately if AF persisted.


Computed tomography angiography (CTA)
Altogether, 44 patients participated in this study, and 30 patients underwent CTA postoperatively for evaluationng the status of the LAA. According to experience from another study 12 and the morphology of the residual LAA observed by CT, three categories of residual LAA of were defined: (1) complete LAA excision (cLAA): the absence of any opacification in the presumed anatomical location of the LAA; (2) incomplete LAA excision (iLAA): the presence of any contrast flow into the residual LAA with any musculi pectinati indicators; and (3) LAA stump (sLAA): the presence of any contrast flow into the residual LAA with no musculi pectinati indicators. Finally, the maximal dimensions were recorded for iLAA and sLAA. The typical LAA morphology by CT is shown in Figure 1.

Follow-up
After surgery, patients were followed up at 1, 3, 6, 9, and 12 months and every 6 months thereafter for the detection of primary and secondary outcomes. Cerebral CT or MRI and 7-day Holter monitoring were performed annually. All cerebral CT and MRI data were reviewed by a stroke specialist. An independent clinical event adjudication committee reviewed the clinical reports of all primary and secondary events.

Statistical analysis






A total of 18 female and 26 male patients were included in this study. Table 1 shows the baseline characteristics of the study population. The mean age was 65.0±9.1 years. The mean CHA2DS2-VASc score was 4.2±1.2, and the mean HAS-BLED score was 3.3±0.7.

Thoracoscopic LAAE and AF ablation
On average, one each surgery procedure took 210 min (range, 120 to 445 min). As only a small amount of blood was lost during surgery, no homologous blood products were used, except in one patient, who received a platelet transfusion of 10 U because of thrombocytopenia. The median postoperative hospital stay was 8 days (range, 5 to 25 days). Among all the patients, 3 had a hospital stay ≥20 days due to pacemaker implantation, uncontrolled atrial arrhythmia, and pulmonary infection, respectively. The chest tube was removed 4 days (range, 2 to 7 days) after surgery in all patients. Hoarseness occurred immediately after the surgery but was spontaneously resolved 3 months later in one patient. Another patient suffered a TIA one day after the surgery. No operative deaths or other major complications, including stroke and cardiac events, occurred.

Follow-up data
    Among these 44 patients, one was lost to follow-up. The mMedian follow-up duration was 780 days, with an  (interquartile range of 656 days Q1-Q3) in the remaining 43 patients. A total of 3 patients underwent pacemaker implantation after the surgery. Another 3 patients underwent radiofrequency catheter ablation due to AF recurrence after the surgical intervention. Among the 38 patients who underwent scheduled long-term electrocardiographic monitoring (24-h or 7-d Holter monitoring), overall success with no AF recurrence was achieved in 16 (84.2%) patients with paroxysmal AF, in 13 (68.4%) with persistent AF, and ; thus, successful AF ablation with no AF recurrence in  29 (76.3%) patients overall.

Thromboembolic events, major bleeding events, and all-cause mortality
All patients discontinued OAC therapy after the surgical intervention. One patient suffered a TIA one day after the surgery. Another patient was diagnosed with a new ischemic stroke at 491 days after surgery. In this patient, AF did not recur, and no sequelae were observed after the recurrent restroke. No systemic thromboembolic events occurred during the follow-up period. The annual rate of total thromboembolism was 2.05%. To date, no patients have died or experienced major bleeding events after the surgery.

Postoperative status of the LAA
According to the postoperative morphology of the residual LAA, among the 30 patients with postoperative CT records 7, 5, and 18 patients showedwere categorized as  iLAA, sLAA, and cLAA. There were no significant differences among the three groups in age, sex, CHA2DS2-VASc score, HAS-BLED score, past history, morbidities, Rankin score or other baseline characteristics.
We measured the maximal dimensions of the residual LAA of each patient by CTA. The mean values were 11.86±3.26 mm and 5.36±1.96 mm in the iLAA and cLAA groups, respectively, with a value of 0 mm in the cLAA group as a control.







This is the first prospective cohort study to assess the clinical outcome of thoracoscopic LAAE plus AF ablation for secondary thromboembolic prevention in a cohort of AF patients with a high risk of bleeding. Our initial experience suggests a promising strategy for managing such high risk patients, in a healthcare setting where warfarin management can be challenging.

The presumed 100 person-year incidence of thromboembolic events in the AF population with a CHA2DS2-VASc score of 4 is approximately 4.0%13. The results from our study show that this interventional approach could yield satisfying outcomes with a very low annual thromboembolic event rate (2.05%) or bleeding events without no anticoagulation OAC treatments or no bleeding events. Compared with other stand-alone secondary prevention approaches, such as anticoagulation treatment, LAA occlusion (LAAO), and stand-alone LAAE in AF patients 11.14-19, the efficacy found in this pilot study is better appears better than that of anticoagulation using warfarin, and similar to that of LAAO and stand-alone LAAE 20.21. Considering thesurgical procedural complications in our study, our combined surgical epicardial AF ablation and LAAE approach seems safe and does not increase the periprocedural risks compared with stand-alone surgical LAAE 9.22 and percutaneous LAAO 23.24.

Challenges of secondary prevention in this double-high-risk population
AF patients with a prior ischemic stroke or TIA are a special double-high-risk population . These patients normally have a higher rate of for recurrent stroke 13.25-27 and . With the application of anticoagulation therapy, the rate of bleeding events increased 28.  , and the restroke rate remained higher than that of the primary prevention method 29. This effect is more pronounced in Asian populations 30, especially in China 31.32. Due to the risk of bleeding events, neurologists in China prescribe anticoagulation drugs to AF patients with a prior stroke much less frequently than those in other global regions 31.33.34.36. 
Poor TTR in China ..
Lack of INR monitoring
Relation of poor TTR to high stroke and bleeds

Novel Non-vitamin K antagonist OACs (NOACs) are supposed to be safer than warfarin in terms of bleeding 36.37. , However,but they were not widely accepted by Chinese AF patients due to their high cost and lack of insurance coverage. For several decades, doctors have struggled with this dilemma between preventing stroke and reducing the risk of bleeding. To solve this problem, we need to develop a novel approach to concurrently prevent thromboembolic events and avoid anticoagulation therapy in this double-high-risk population. Currently, LAAO is considered an alternative approach for stroke prevention 38; however, periprocedural antiplatelet plus anticoagulation therapy might not be suitable for such patients with a high risk of bleeding. Furthermore, for the patients with short-lasting,symptomatic persistent and paroxysmal AF in this population, only performing LAAO without an AF rhythm intervention is not an ideal strategy.

Surgical LAA intervention
Because the LAA accounts for nearly 90% of the atrial clots in nonvalvular AF patients 39, many efforts have been made by surgeons to treat the LAA for stroke prevention. Generally, these surgical approaches involve either surgical sutures (epicardial, endocardial, amputation or epicardial) or surgical devices (AtriClip or ENDOLOOP) 40. Although these procedures are usually conducted concomitant with other cardiac surgeries, they have shownseem to have positive results in terms of the long-term efficacy of stroke prevention41.42. 
Recently, Toshiya Ohtsuka et al. applied stand-alone left atrial appendectomy has also been used for stroke prevention in nonvalvular AF patients 9.43. 
The results showed that this minimally invasive approach is potentially safe 9 and acceptable for stroke prevention without anticoagulants. This study highlights that minimally invasive LAAE could be an alternative approach for stroke prevention in nonvalvular AF patients with a high risk of bleeding. Thus, we conducted this pilot study to determine whether AF ablation could be performed simultaneously and further improve the clinical outcome.

Thoracoscopic surgical AF ablation and LAAE
Standard thoracoscopic surgical AF ablation comprises epicardial pulmonary vein isolation and appendage excision 44.45. This minimally invasive technique has been proven to be a safe procedure and can be recommended as a useful alternative procedure for nonvalvular AF patients 46. Due to its AF rhythm control and appendectomy, we hypothesize that this is a unique procedure suitable for double-high-risk AF patients. The AF control rate in paroxysmal and persistent AF patients in the study cohort was 84.2% and 68.4%, respectively. 

Previous studies have demonstrated that iLAA or sLAA after stand-alone LAAE could increase the rate of thromboembolic events 47.48, but these results were not observed during the two-year follow-up period of the current study despite athe iLAA rate prevalence of 23.33% and sLAA rate prevalence of 16.67%. We speculate that this limitation may be overcome by AF rhythm control. Additionally, our study initial experience further verifies the safety and feasibility of this approach, to be explored in larger studies. The minimal invasiveness, low complication rate, short hospital stay and lack of anticoagulation treatment of this approach support its use as a first-line therapy in this double-high-risk population in tertiary hospitals. 

Limitations
The major limitations of this study are the small sample size and lack of a control group. Because this was a pilot study and for exploring the efficacy and safety of the approach, a controlled trial or large cohort study should be performed in the future after establishment of the methodology. In addition, the Rankin score of the study cohort was relatively small, and the results of this study cannot be extrapolated to all AF patients with prior thromboembolic events.

Conclusions
Trans-thoracoscopic LAAE plus AF ablation may be a promising approach for this high-risk population. Thromboembolism prevention in this secondary prevention cohort was low, even without OAC treatment.


AF patients with prior thromboembolic events and a high risk of bleeding are part of a “double-high-risk” population. Thoracoscopic minimally invasive LAAE plus surgical AF ablation is a promising approach for this unique population. Further randomized clinical trials and large cohort studies are necessary to verify the suitability of this approach as a first-line therapeutic strategy in this population.
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Modified Rankin Score (Mean±SD)	0.7±0.9
Thromboembolic events	
  Prior ischemic stroke	44 (100.0%)
  Prior TIA	3 (6.8%)
  Prior systemic embolism	1 (2.3%)
Bleeding history	





Congestive heart failure	3 (6.8%)
Use of OAC before admission	
  Warfarin	17 (38.6%)





Figure 1 Three typical morphology of LAA in CT pre- and post-procedure
Fig 1A Representative CT images of three morphology of residual LAA pre- and post-procedure. Titanium clip is shown in the red circle (pointed by red arrow). Residual LAA is shown in the yellow circle (pointed by yellow arrow).
Fig 1B Representative three-dimensional reconstructions of three morphology of residual LAA pre- and post-procedure. Pre-procedural LAA is pointed by the white arrow, with representative LAA region shown in the white circle. Post-procedural residual LAA is shown in yellow color and pointed by yellow arrow.
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